US Food and Drug Administration gets it right.
D002318:Cardiovascular Diseases / Q000139:chemically induced; D056486:Chemical and Drug Induced Liver Injury; D051546:Cyclooxygenase 2; D017277:Drug Approval; D006801:Humans; D007527:Isoenzymes / Q000009:adverse effects; D007555:Isoxazoles / Q000009:adverse effects; D000077339:Leflunomide; D008565:Membrane Proteins; D011451:Prostaglandin-Endoperoxide Synthases / Q000009:adverse effects; D011996:Records; D006113:United Kingdom; D014481:United States; D014486:United States Food and Drug Administration
D007527:Isoenzymes; D007555:Isoxazoles; D008565:Membrane Proteins; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D000077339:Leflunomide